Member Info for Retireby40

So chazzy is saying we are detecting covid-19 (as well as other containments) in the Winter Olympics. Is that right?

Fair enough. It’s in a long line of exaggeration but yeah no need for profanities.

I’ll do as I please thanks. He has tweeted that we are helping to detect covid-19 so are we? I can’t see that in the RNS. Look forward to you clarifying.

Yeah maybe I’ve been OTT there but it doesn’t say that in the RNS so he shouldn’t say that on Twitter. More unnecessary confusion.

Gerry doesn’t help himself, yet more unprofessional Bull**** from Gerry-

https://twitter.com/gjbrandon/status/1479042980438810626?s=21

This is how York-based @DeepVerge is helping to detect Covid-19 at the Beijing 2022 Winter Olympics yorkshirepost.co.uk/business/this-? #YorkshirePost

A shame we cannot get into these large cruise cos -
Initially, the cruise line reported 44 cases on board. "This number (48) includes four additional close contacts which were identified as COVID-19 positive at the end of the voyage," Sierra-Caro said Monday. "The guests were quarantined on board and assisted upon the ship’s arrival on Dec. 18."
All passengers 12 and older were required to be fully vaccinated and to test negative to board the Symphony of the Seas ship. The ship sailed with 95% of the onboard community fully vaccinated on the Dec. 11 to Dec. 18 cruise, with 98% of those people who tested positive being fully vaccinated, Royal Caribbean said.

Mirriad working with Lexus via Music Alliance but a huge number of partners to place with -

https://twitter.com/mirriad/status/1471447565346426883?s=21

You won’t see that happening in the South as they adhere to the EU rules which we used to. Funnily enough UK has massively upped the dumping since we left. Another Brexit bonus.

Anyone know what happening with our partnership with Parity?

We have a CE mark for professional use.

Erm things change. Just because that was the plan at the time of the raise doesn’t mean they can’t in a different direction. Whatever creates most shareholder value.

It’s surely obvious to many that being a broad based generic anti-viral many govs will want this stockpiled. Let’s not forget the amount of safety data collected the the fact many majors will also look at the massive COPD market. I hope/expect we will be taken over in H1 next year. Hopefully once topline results are published we’re taken over so no decisions on top slicing etc!

I don’t believe the Avacta ceo is responsible for the UK’s joke validation process or indeed making decisions on HUA in EU. It’s a matter of time IMO. Validated in Madrid and submitted to a notified body there for HUA. A matter of time with the outstanding validation and lay-user data.

Surely it’s ABDX

It’s unprofessional and most fund managers (or sophisticated investors) looking on would not be impressed. He’s a CEO FFS.

Anyway, a good RNS is the main thing. Have a good weekend all.

I said I would stay away until a material RNS and we have had it. I wasn’t surprised as many wouldn’t have been given yesterday’s Twitter activity. I should’ve gone with guy and bought some to sell this morning. It’s a good RNS, no doubt so well done. Not surprised China resources delayed, hopefully they can get out there early next year snd close.

What I stand by is more amateurish behaviour. Pumping on Twitter yesterday and an RNS lands this morning. Little wonder we went high and are now down.

Should’ve left Twitter alone and let the RNS land, have the proactive video and reinforced the material news on Twitter after the RNS rather than nudge nudge wink wink before. Same old and same old result.

Estimated revenue this year is $6m with nearly $30m loss and best in mind they have never hit guidance next year estimate is $10m with $24.7m loss so one assumes that will be a lower revenue base and higher loss. Another raise looks nailed on. At least Richards is consistent in raising cash albeit I suspect a large discount incoming.

https://www.edisongroup.com/wp-content/uploads/2021/12/WANdisco-One-exabyte-of-data-to-Google-cloud-for-6m-2.pdf

So we are expecting news that Abbingdon is able to mass produce our test this month (according to their RNS) and we are hoping for APAC news this month. Surely a yay or nay from EU on HUA due soon too. Outstanding results and independently done in Madrid and submitted to a notified body there. Hurry the duck up!!
Avacta is working with additional distributors in the Asia Pacific (APAC) region, and in other territories, to obtain the additional local regulatory approvals to place an IVD product with a CE mark on the market in those territories. These approvals are expected to be received in Q4 2021 which would allow for sales in those additional territories.
It is now widely expected that SARS-CoV-2 antigen testing will be a long-term market and will become a seasonal testing market similar to that for influenza. The high quality and excellent performance of the AffiDX (R) SARS-CoV-2 antigen lateral flow test puts Avacta in a strong position to gain market share in this long-term diagnostic market. In 2020 the total global SARS-CoV-2 antigen test market size (including PCR and other antigen test formats) was valued at $5.3 billion and is expected to expand at a compound annual growth rate of 6.7% from 2021 to 2027 ( source ).
The APAC region accounted for the largest portion of the market so far for SARS-CoV-2 antigen testing, representing 37.0% of the market in 2020(1) and, in the lateral flow testing market, there is a shift globally towards self-testing products. These market trends are key drivers of Avacta's AffiDX (R) SARS-CoV-2 antigen lateral flow test commercial strategy - to expand regulatory approvals in the APAC region and to bring a self-test product to market.
The regulatory approval of a self-test version of the AffiDX(R) SARS-CoV-2 antigen lateral flow test is a critical milestone because self-administered testing represents a significantly larger commercial opportunity than professional use testing. Avacta is working closely with its partner Medusa19 to support Medusa19's application for a CE mark for an AffiDX(R) SARS-CoV-2 antigen self-test. Good progress is being made in this regard with the submission of the regulatory documentation to a notified body in Europe. Medusa19 and Avacta are currently awaiting the response of the notified body and will update the market when a response is received.
The AffiDX(R) SARS-CoV-2 antigen lateral flow test is being manufactured by Global Access Diagnostics and the transfer of this process to Abingdon Health is now being validated to allow commercial product to be manufactured and released. In combination these two UK-based manufacturers will be able to supply 3-5 million tests per month. Further capacity, if required, is being put in place in Europe and potentially in Asia

I apologise if I have some across as disrespectful as I’ve no doubt you’re (GB) working as hard as ever. I stand by some of my irks re social media comments and triple digit growth nonsense and given the MWG orders and the fact we have not guided more than £10m that labskin stagnant. Hope to be proven wrong!

Anyway, I sold circa 1m shares over many, many months in an orderly fashion as I always
Planned to keep a decent portion.

Having met you and thought highly of you I do feel bad venting on here so apologies.

I’ll give DVRG BBs a wide birth until material RNSs land and hope to be pleasantly surprised.

Best wishes all.

Minded GB’s wife dumped shared not far from double where we are and GB made a stupid point about it around Valentine’s Day on Twitter, so unprofessional and quite rankle embarrassing. I wasn’t actually moaning about the awful share price but (I repeat) am alarmed that labskin’s is seemingly in reverse from where it was last year. That is a fair point to make. As great as all these other services could be that is our core competence (bread snd butter).

As I said I’ve been invested for 3 years and know the business and services well as well as the RNSs in the last few years. I used to love his enthusiasm but there is a line and he crosses it too often. He bigged up £2.4m in Q4 (only a few weeks for MWG) and said momentum continued into 2021 and then we have H1 results. Anyway, let’s see what the next couple of RNSs bring.

*in-vitro